Pharmacogenetic Clinical Randomised Phase II Trial to Evaluate the Efficacy and Safety of FOLFIRI With High-Dose Irinotecan (HD-FOLFIRI) in Metastatic Colorectal Cancer Patients According to Their UGT1A 1 Genotype
British Journal of Cancer - United Kingdom
doi 10.1038/s41416-018-0348-7
Full Text
Open PDFAbstract
Available in full text
Date
December 26, 2018
Authors
Publisher
Springer Science and Business Media LLC